BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...neuromuscular junctions. For further support, Hayden pointed to the studies of Nuedexta dextromethorphan hydrobromide from Avanir Pharmaceuticals Inc....
...a statistically significant effect on reducing pseudobulbar effect in patients with ALS and multiple sclerosis. Avanir...
BioCentury | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

...Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint...
...used in 15-AVP-786-302 (see "Avanir's AVP-786 Meets in Phase III for Alzheimer's Agitation" ). The Avanir Pharmaceuticals Inc....
...II testing for schizophrenia, intermittent explosive disorder and neurobehavioral dis-inhibition associated with traumatic brain injury. Avanir...
BioCentury | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

...Score from baseline to week 12 vs. placebo. However, a second dose missed the endpoint. Avanir Pharmaceuticals Inc....
...by a priori response criteria and re-randomized to receive either dose of AVP-786 or placebo. Avanir...
...weighted from both stages of the treatment periods was used to analyze the primary endpoint. Avanir...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Development and Commercialization Inc. affiliate of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan), and CMO of Avanir Pharmaceuticals Inc....
BioCentury | Dec 21, 2018
Company News

Otsuka's Avanir to terminate Onzetra license

...OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate...
...migraine drug Onzetra Xsail in the U.S., Canada and Mexico (see "Avanir, OptiNose deal" ). Avanir...
...Japan Business: Drug delivery, Neurology Shannon Lehnbeuter Onzetra Xsail, sumatriptan nasal powder (avp-825, Intranasal sumatriptan powder, OptiNose sumatriptan) Avanir Pharmaceuticals Inc. OptiNose...
BioCentury | Oct 26, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

...of strategy and transformation, global R&D. CEO Palekar is the former CEO of neurology company Avanir Pharmaceuticals Inc....
BioCentury | Oct 25, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

...of strategy and transformation, global R&D. CEO Palekar is the former CEO of neurology company Avanir Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

...acquisitions by Otsuka of U.S. companies include ADHD company Neurovance Inc. in 2017, CNS company Avanir Pharmaceuticals Inc....
BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

...acquisitions by Otsuka of U.S. companies include ADHD company Neurovance Inc. in 2017, CNS company Avanir Pharmaceuticals Inc....
BioCentury | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

...Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) hired Richard Malamut as CMO. He was CMO at Avanir Pharmaceuticals Inc....
Items per page:
1 - 10 of 462
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...neuromuscular junctions. For further support, Hayden pointed to the studies of Nuedexta dextromethorphan hydrobromide from Avanir Pharmaceuticals Inc....
...a statistically significant effect on reducing pseudobulbar effect in patients with ALS and multiple sclerosis. Avanir...
BioCentury | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

...Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint...
...used in 15-AVP-786-302 (see "Avanir's AVP-786 Meets in Phase III for Alzheimer's Agitation" ). The Avanir Pharmaceuticals Inc....
...II testing for schizophrenia, intermittent explosive disorder and neurobehavioral dis-inhibition associated with traumatic brain injury. Avanir...
BioCentury | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

...Score from baseline to week 12 vs. placebo. However, a second dose missed the endpoint. Avanir Pharmaceuticals Inc....
...by a priori response criteria and re-randomized to receive either dose of AVP-786 or placebo. Avanir...
...weighted from both stages of the treatment periods was used to analyze the primary endpoint. Avanir...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Development and Commercialization Inc. affiliate of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan), and CMO of Avanir Pharmaceuticals Inc....
BioCentury | Dec 21, 2018
Company News

Otsuka's Avanir to terminate Onzetra license

...OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate...
...migraine drug Onzetra Xsail in the U.S., Canada and Mexico (see "Avanir, OptiNose deal" ). Avanir...
...Japan Business: Drug delivery, Neurology Shannon Lehnbeuter Onzetra Xsail, sumatriptan nasal powder (avp-825, Intranasal sumatriptan powder, OptiNose sumatriptan) Avanir Pharmaceuticals Inc. OptiNose...
BioCentury | Oct 26, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

...of strategy and transformation, global R&D. CEO Palekar is the former CEO of neurology company Avanir Pharmaceuticals Inc....
BioCentury | Oct 25, 2018
Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

...of strategy and transformation, global R&D. CEO Palekar is the former CEO of neurology company Avanir Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

...acquisitions by Otsuka of U.S. companies include ADHD company Neurovance Inc. in 2017, CNS company Avanir Pharmaceuticals Inc....
BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

...acquisitions by Otsuka of U.S. companies include ADHD company Neurovance Inc. in 2017, CNS company Avanir Pharmaceuticals Inc....
BioCentury | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

...Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) hired Richard Malamut as CMO. He was CMO at Avanir Pharmaceuticals Inc....
Items per page:
1 - 10 of 462